XRP Liquidity Just Got Absolutely Crushed. Here’s What Happened
The CVD dropped from near-neutral levels to approximately -1.18 billion. Both moving averages on the chart continue trending lower.
The CVD measures the net difference between buying and selling volume over time. A collapse of this scale signals that sellers have dominated the market consistently, not in isolated bursts.
Reading the Chart
The TradingView chart Xaif shared tells a clear story. CVD held near 0 through early October. Around October 12 to 13, it broke sharply lower. A brief stabilization followed, then another leg down accelerated the decline through October 17 to 19.
The green moving average has curved steeply downward. The purple moving average lags behind but follows the same trajectory. Neither shows any sign of flattening. The most recent CVD reading on the chart sits near -1.18 billion, with the price of XRP at 1.2983.
The sustained decline in CVD shows consistent net selling across the observed period, not a single event.
Capitulation or Continuation
Xaif closes with the central question: “is this capitulation, or is there more selling left?” Some analysts believe the short-term future is bearish, and that question carries real weight given the chart’s structure.
Capitulation typically refers to a final, exhaustive wave of selling that precedes a reversal. The CVD data does not yet confirm that condition.
Community Responses
The responses from other analysts add important context to Xaif’s observation.
The Current Picture
The CVD data shows sustained selling pressure in XRP’s market. The moving averages have not turned. No divergence between price and CVD has appeared. Analysts watching the chart are split between those who see distribution continuing and those who sense exhaustion setting in.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GBP/JPY Price Forecast: Bulls eye 211.10 as bearish trend persists
CERo Therapeutics Adds UC Davis as Site for Phase 1 CER-1236 Trial in Blood Cancers
TWFG publishes update to financial calendar
YHN Acquisition I Faces Nasdaq Delisting After Failing Market Value Requirements
